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ABSTRACT 
This study was designed to evaluate the efficacy of low-dose of oral acetylsalicylic acid (aspirin) with focal argon laser 
for the treatment of acute central serous chorioretinopathy (CSCR). In this prospective case-control study, 40 Patients 
with acute CSCR were classified randomly to two groups; group A with no treatment as the control group and group B 
with argon Laser in focal treatment once, followed by aspirin, 100 mg per day orally, with follow up period of 12 
months by evaluation of visual acuity, and by Optical Coherence Tomography (OCT), every three months for one year. 
Patients in the second group treated with argon Laser and aspirin showed more clinically significant improvement in 
both visual acuity and OCT macular thickness by the end of the follow-up period when compared with the 
observational group. It was concluded that argon Laser with low-dose oral aspirin results in improvement of visual 
acuity and OCT macular thickness. 
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INTRODUCTION
Central Serous Chorioretinopathy (CSCR) is a posterior 
segment disease that usually effects young males in their 
third and fourth decade of life [1, 2]. Neurotic patients, 
or those, who are experiencing psychological stress were 
at higher risk of developing CSCR [3, 4]. Fluid 
accumulation between the neuroretina and Retinal 
Pigment Epithelium (RPE) is the main pathophysiology of 
CSCR. Its predilection of site is the posterior pole, leading 
to early central vision loss, scotoma, metamorphopsia, 
and/or micropsia [5, 6]. 
Fluorescein Angiography (FA) is of great value in the 
diagnosis of CSCR, confirming the focal point of leakage 
with fluorescein diffusion in the form of a ‘smokestack' 
pattern, or ‘expansile dot pattern ' appearance under a 
serous neuroretinal detachment. The CSCR may be 
solitary or have multiple leaking points [7-9]. Optical 
Coherence Tomography (OCT) is helpful in visualization 
of morphologic changes occurring in the retinal layers 
and the detachment occurring in the RPE, while it could 
also be used to track the disease evolution [10-13]. 
 Observation is the first line treatment of CSCR, as the 
disease is self-limiting with non-permanent effects of the 
first episodes of acute CSCR being likely in most patients. 
The patient should be followed-up regularly to confirm 
resolving of the neurosensory detachment, which 
normally occurs within a period of three to four months, 
however, the rate of recurrence is considerably high [5, 
14]. 
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Focal argon laser photocoagulation application to the 
point of leakage has become a vastly practiced line of 
management for acute CSCR. The treatment aims to 
produce a ‘sealing' of the RPE defect, guided by 
fluorescein angiography. Furthermore, the retinal laser 
photocoagulation stimulates closer RPE cells, thus, 
promotes the pump function of the RPE [15-17]. 
Acetylsalicylic acid (Aspirin), at a low dose, has been 
reported to be beneficial in the treatment of CSCR 
through its anti-platelets effects and by reducing serum 
levels of Plasminogen Activator Inhibitor 1 (PAI-1) [18, 
19]. The aspirin treatment effect depends on the 
hypothesis of impaired fibrinolysis in conjunction with 
augmented platelet aggregation in the choriocapillaris in 
CSCR pathogenesis [20]. 
To the best of the author’s knowledge, there are no 
studies, which have evaluated the effectiveness of 
combined focal argon laser with low-dose of oral aspirin 
in treatment of Central Serous Chorioretinopathy (CSCR). 
The purpose of this prospective study was to evaluate 
the efficacy of both laser and aspirin together, in 
comparison to observation alone. 
MATERIALS AND METHODS 
This was a prospective case-control study, including 
patients with acute CSCR, presented to the 
Ophthalmology Department of Sohag University Hospital, 
Egypt, between January 2016 and July 2016. Exclusion 
criteria were presence of ocular or retinal disease other 
than CSCR, history of previous attacks of CSCR, history of 
coagulation problems or bleeding tendencies, previous 
retinal laser photocoagulation, history of peptic ulcers, 
pregnancy, or aspirin allergy. 
Forty eyes of 40 patients with CSCR were classified 
randomly to two groups, according to their involved eye 
being right or left. Patients with pathology in their right 
eye were assigned to group A and when CSCR was in the 
left eye, patients were assigned to group B. Each group 
included twenty patients; group A with no treatment as 
the control group and group B with argon laser as the 
focal treatment once, followed by aspirin 100 mg per 
day, orally, for 12 months. 
The Declaration of Helsinki was respected throughout 
the study. Approval was obtained from Sohag Faculty of 
Medicine committee and all patients signed written 
informed consents for the treatment sequence. 
 All patients were subjected to complete ophthalmic 
evaluation, including Corrected Distance Visual Acuity 
(CDVA) measurement by the Snellen chart, which was 
converted to a logarithm of the minimum angle of 
resolution (logMAR), measurement of the Intraocular 
Pressure (IOP), using I Care tonometer, indirect 
ophthalmoscopy (Heine 2000 Ophthalmoskop, Heine; 30-
D lens, Zeiss), slit lamp biomicroscopy, FA (TRX fundus 
camera, Topcon Medical Systems, Inc.), and macular OCT 
(OPTOVUE RTvue) at the first-time visit (baseline). 
Fluorescein angiography was used to identify the leakage 
point and Volk area centralis contact lens (Keeler Ltd, 
Clewer Hill Road, Windsor, Berks, SL4 4AA) laser was 
applied using spot size of 100 microns, duration of 100 to 
200 milliseconds, and power of 150 to 400 milli Watts 
(mW) in all subjects. 
Follow-up of all patients was done over a period of 
twelve months; follow up visits were scheduled on the 
first, third, sixth, and twelfth month. The follow up 
regimen included CDVA in logMAR, IOP, slit lamp 
biomicroscopy, indirect ophthalmoscopy, fundus 
photography, and Central Macular Thickness (CMT) by 
macular OCT, done during every visit. 
Statistical analysis was conducted by SPSS for Windows 
version 10.0 software (SPSS Inc., Chicago, IL, USA) to 
compare parameters of both groups and a P value of 
≤0.05 was considered statistically significant. 
RESULTS 
A total of 40 eyes of 40 patients were enrolled for this 
prospective study, 29 were males (72.5%) and 11 females 
(27.5%). The mean ± standard deviation (SD) age was 
29.8 ± 4.8 years (range 19 to 40). Demographic and initial 
visit data for both groups are shown in Table 1, which 
were insignificant. 
Table 1: Demographic and Baseline Visit Data for Both Groups 
 Group A Group B P Value 
Eyes (n) 20 20  
Age, years (mean ± SD) 26.3 ± 3.7 29.4 ± 4.9 0.731 
Gender    
Male (n) 13 16  
Female (n) 7 4  
Mean CDVA (Log MAR) (mean ± SD) 0.532 ± 0.16 0.541 ± 0.136 0.894 
Mean CMT in microns 468.1 ± 28.32 453.9 ± 34.65 0.764 
Data are presented as Mean ± SD M: male; F: female; Log MAR: logarithm of the minimum angle of resolution; CDVA: corrected distance visual acuity; 
CMT: central macular thickness; SD: standard deviation; n: number 
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Table 2: Mean Corrected Distance Visual Acuity Follow up Data for Both Groups in One Year 
 Group A Group B P Value 
Pre mean Log MAR CDVA 0.532 ± 0.16 0.541 ± 0.136 0.894 
Post 1m mean Log MAR CDVA 0.478 ± 0.12 0.309 ± 0.102 0.187 
Post 3m mean Log MAR CDVA 0.412 ± 0.141 0.246 ± 0.139 0.081 
Post 6m mean Log MAR CDVA 0.387 ± 0.11 0.211 ± 0.121 0.064 
Post 12m mean Log MAR CDVA 0.373 ± 0.21 0.174 ± 0.181   0.034* 
Data are presented as Mean ± SD 
SD: standard deviation; CDVA: corrected distance visual acuity; Log MAR: logarithm of the minimum angle of resolution; m: months.  
* P values less than 0.05 
 
Table 3: Mean Central Macular Thickness (CMT) Follow up Data for both Groups During One Year 
 Group A Group B P Value 
Pre mean CMT 468.1± 28.32 453.9±34.65 0.764 
Post 1m mean CMT 332.1± 26.32 311.9±30.25 0.257 
Post 3m mean CMT 305.1± 28.32 283.9±30.65 0.066 
Post 6m mean CMT 301.1± 34.32 276.9±27.61   0.049* 
Post 12m mean CMT 281.1± 29.12 262.2±31.75   0.034* 
Data are presented as Mean ± SD 
SD: standard deviation; CMT: central macular thickness; m: months. * P values less than 0.05 
 
 
 
Figure 1: Group A: A) At diagnosis: Macular detachment due to acute Central serous chorioretinopathy (CSCR). B,C) At 6th and 12th month, 
respectively: Minimal improvement with no resolution. Group B: A) At diagnosis: Macular detachment due to acute CSCR. B,C) At 6th and 12th months, 
respectively: Marked improvement with complete resolution. 
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Figure 2: Fluorescein Angiography of Acute Central Serous Chorioretinopathy (CSCR). A) At diagnosis: Macular Leakage due to acute CSCR. B,C) At 6th 
and 12th months, respectively: Marked improvement with no leakage after combined argon laser and low dose aspirin treatment. 
 
The mean CDVA follow up data for one year, as 
summarized in Table 2, improved in both groups with no 
statistically significant difference in all follow ups, except 
at 12 months, when there was a statistically significant 
difference between both groups with greater 
improvement in group B (P=0.034). 
The mean CMT follow up data for one year, as 
summarized in Table 3, improved in both groups with 
statistically significant difference only at the six (P=0.049) 
and twelve-month (P=0.034) follow up with more 
improvement in group B (Figures 1 and 2). 
Four cases showed persistence of CSCR with no 
improvement and two cases of recurrence were 
identified in group A. Group B showed no cases of 
persistence of the CSCR and one case of recurrence 
(Table 4).  
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Table 4: Number of recurrences and persistent central serous 
chorioretinopathy cases in both groups 
 Group B Group A 
Persistence of the CSCR  4 0 
Recurrence of the CSCR  2 1 
CSCR: Central serous chorioretinopathy. 
 
DISCUSSION 
In Central Serous Chorioretinopathy (CSCR) serous 
detachment of the neurosensory retina occurs over an 
area of choriocapillary leakage, through the RPE. The 
pathophysiology is not well understood, however, focal 
choroidal vasculopathy and hyperpermeability areas are 
proposed hypotheses of focal choroidal vascular 
compromise. Some researchers stated that initial 
choroidal vascular compromise leads to secondary 
dysfunction of the overlying RPE [19, 21, 22]. 
The focus of attention in the current study was the effect 
of combination of both surgical and medical treatment in 
cases of classic CSCR. The surgical intervention was focal 
argon laser therapy by FA guide, and medical treatment 
was long-term low dose of aspirin. This study attempted 
to evaluate the effectiveness of this new technique by 
studying the level of improvement either clinically by 
CDVA or anatomically by measurement of CMT by OCT. 
For a long time, argon laser photocoagulation alone has 
been an effective method for management of CSCR. 
Many studies confirmed the efficacy and safety of focal 
laser photocoagulation to the leaking RPE by FA guide 
[23]. The current researchers agreed with Novak et al. in 
usage of argon laser for photocoagulation [24], however, 
many alternatives for photocoagulation were used: 
Mitsui et al. [25] used Xenon laser while Slusher et al. 
[26] used Krypton Laser, Elsner et al. used photodynamic 
therapy (PDT) [27], and GuptaB et al. used micropulse 
diode laser [28]. Transpupillary Thermotherapy (TTT) by a 
810-nm long-pulse low-energy diode laser was also used. 
The mechanism of action was increasing the temperature 
of the choroid and outer retina and sparing the vital 
inner retina and photoreceptors to some extent, 
however, the exact mechanism is not obvious [29, 30]. 
In the current study, the researchers demonstrated 
improvement in both duration and final outcome, 
however, Fok et al. [31] reported that laser 
photocoagulation hastened the resolution, yet had no 
effect on the final visual outcome nor the rate of 
recurrence; this discrepancy may be due to addition of 
aspirin in the current case group.  
This study agrees with Spalter’s study, which reported 
effectiveness of the Argon laser photocoagulation for 
acute CSCR in clearly defined focal leakage point on FA. 
The regenerating cells then slide over and obliterate the 
pigment epithelial defect responsible for the lesion. 
However, in his study, side effects, such as laser scar 
formation, permanent scotoma, and laser-induced 
choroidal neovascularization was reported, which was 
not recorded in the current study; this may be due to low 
energy used with minimal power shots [32]. 
In the current study, the researchers used medical 
treatment in the form of aspirin, orally, at a dose of 100 
mg per day for 12 months. Caccavale et al. [18] used 
aspirin, orally, at the same dose for six months and 
reported that treatment with low-dose aspirin may result 
in speeding of visual rehabilitation and decreasing 
incidence of recurrence in CSCR cases compared with the 
untreated control group, which was parallel with the 
current findings. 
In the current study, the mean CDVA in group B (Aspirin 
and laser) at diagnosis was 0.541 ± 0.136, which 
improved to 0.174 ± 0.181 at 12 months (p value = 
0.034). This result coincides with a previous study, which 
suggested that effectiveness of aspirin therapy impaired 
fibrinolysis and increased platelet aggregation hypothesis 
in the choriocapillaris, as the possible cause of the 
pathogenesis of CSCR [20]. Kurup et al. used low-dose of 
methotrexate [23] and Forooghian et al. [33] used 
finasteride mineralocorticoid receptor antagonist, yet 
both studies did not achieve encouraging results. Lim et 
al. [34] found no positive effect for intraocular 
bevacizumab injection in classic CSCR cases compared 
with the control group. 
Meyerle et al. [35] also used ketoconazole as a medical 
treatment for CSCR to decrease endogenous cortisol 
synthesis, however, they noted that there is no 
improvement in outcome in a preliminary study or in 
their later clinical trial. 
Also, the significant improvement of mean CDVA in group 
B coincides with the study of Burumcek et al., [8] in 
which the final Best-Corrected Visual Acuity (BCVA) was 
better (P value = 0.003) in the CSCR group treated with 
laser photocoagulation than that of the control group. 
Regarding changes in the CMT, in group B, mean CMT 
decreased by 453.9 ± 34.65 microns from diagnosis to 
the 12th month with statistically significant differences in 
the 6th and 12th month follow up, in comparison to 
Group A (P value = 0.049; P value = 0.034, respectively). 
On the whole, it was noted that the functional 
improvement (represented in the CDVA) and anatomical 
improvement (OCT macular thickness) in group B treated 
by both argon laser and aspirin were more than group A. 
The main limitation of the current study was the 
relatively small number of cases and short period of 
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follow up. Further studies are warranted with larger 
sample sizes and longer follow up periods. More groups 
with different treatment modalities can be established to 
evaluate the efficacy of each treatment line. 
CONCLUSION 
Argon laser combined with low-dose oral aspirin resulted 
in greater improvement both clinically, by visual acuity, 
and anatomically, by OCT macular thickness 
measurement, compared to observation alone, however, 
future randomized clinical trials with a larger sample size 
and longer follow up period are recommended. 
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